{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T07:40:51Z","timestamp":1769154051556,"version":"3.49.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,10,31]],"date-time":"2016-10-31T00:00:00Z","timestamp":1477872000000},"content-version":"vor","delay-in-days":304,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2016]]},"DOI":"10.6061\/clinics\/2016(10)06","type":"journal-article","created":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T10:34:11Z","timestamp":1480588451000},"page":"586-592","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients"],"prefix":"10.1016","volume":"71","author":[{"given":"Roberto","family":"Hegg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Mattar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Neto","given":"Jo\u00e3o Nunes","family":"de Matos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luiz","family":"Pedrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabina Bandeira","family":"Aleixo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto Odebrecht","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Junior","given":"Renato Peixoto","family":"Cramer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"van-Eyll-Rocha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.6061\/clinics\/2016(10)06_bib1","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/CCO.0b013e32832c9651","article-title":"Should the indications for the use of myeloid growth factors for the prevention of febrile neutropenia in cancer patients be extended?","volume":"21","author":"Klastersky","year":"2009","journal-title":"Curr Opin Oncol"},{"issue":"9","key":"10.6061\/clinics\/2016(10)06_bib2","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1002\/cncr.20983","article-title":"Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy","volume":"103","author":"Caggiano","year":"2005","journal-title":"Cancer"},{"issue":"2","key":"10.6061\/clinics\/2016(10)06_bib3","doi-asserted-by":"crossref","first-page":"328","DOI":"10.7326\/0003-4819-64-2-328","article-title":"Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia","volume":"64","author":"Bodey","year":"1966","journal-title":"Ann Intern Med"},{"issue":"Suppl 1","key":"10.6061\/clinics\/2016(10)06_bib4","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S0959-8049(99)00259-2","article-title":"Chemotherapy dose reduction and delay in clinical practice. evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer","volume":"36","author":"Chang","year":"2000","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.6061\/clinics\/2016(10)06_bib5","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cncr.11882","article-title":"Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management","volume":"100","author":"Crawford","year":"2004","journal-title":"Cancer"},{"issue":"9472","key":"10.6061\/clinics\/2016(10)06_bib6","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2005","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.6061\/clinics\/2016(10)06_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-200262001-00001","article-title":"Colony-stimulating factors for the management of neutropenia in cancer patients","volume":"62","author":"Dale","year":"2002","journal-title":"Drugs"},{"issue":"6","key":"10.6061\/clinics\/2016(10)06_bib8","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1086\/339215","article-title":"2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer","volume":"34","author":"Hughes","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.6061\/clinics\/2016(10)06_bib9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3816\/CBC.2002.n.030","article-title":"Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel\/doxorubicin\/cyclophosphamide: results of the BCIRG 004 trial","volume":"3","author":"Nabholtz","year":"2002","journal-title":"Clin Breast Cancer"},{"issue":"19","key":"10.6061\/clinics\/2016(10)06_bib10","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","article-title":"2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline","volume":"24","author":"Smith","year":"2006","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.6061\/clinics\/2016(10)06_bib11","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1002\/cncr.11827","article-title":"Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma","volume":"98","author":"Lyman","year":"2003","journal-title":"Cancer"},{"issue":"6","key":"10.6061\/clinics\/2016(10)06_bib12","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1634\/theoncologist.10-6-427","article-title":"Risk models for predicting chemotherapy-induced neutropenia","volume":"10","author":"Lyman","year":"2005","journal-title":"Oncologist"},{"issue":"18","key":"10.6061\/clinics\/2016(10)06_bib13","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJM199305063281808","article-title":"Management of fever in patients with cancer and treatment-induced neutropenia","volume":"328","author":"Pizzo","year":"1993","journal-title":"N Engl J Med"},{"key":"10.6061\/clinics\/2016(10)06_bib14","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1200\/JCO.2002.10.058","article-title":"Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial","volume":"20","author":"Osborne","year":"2002","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.6061\/clinics\/2016(10)06_bib15","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1073\/pnas.82.5.1526","article-title":"Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor","volume":"82","author":"Welte","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.6061\/clinics\/2016(10)06_bib16","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1182\/blood.V88.6.1907.bloodjournal8861907","article-title":"Filgrastim (r-metHuG-CSF): the first 10 years","volume":"88","author":"Welte","year":"1996","journal-title":"Blood"},{"issue":"12","key":"10.6061\/clinics\/2016(10)06_bib17","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/S0301-472X(99)00112-5","article-title":"A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans","volume":"27","author":"Molineux","year":"1999","journal-title":"Exp Hematol"},{"issue":"1","key":"10.6061\/clinics\/2016(10)06_bib18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/annonc\/mdg019","article-title":"A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy","volume":"14","author":"Green","year":"2003","journal-title":"Ann Oncol"},{"issue":"6","key":"10.6061\/clinics\/2016(10)06_bib19","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/annonc\/mdf130","article-title":"Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer","volume":"13","author":"Holmes","year":"2002","journal-title":"Ann Oncol"},{"issue":"15","key":"10.6061\/clinics\/2016(10)06_bib20","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.ejca.2006.05.002","article-title":"EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours","volume":"42","author":"Aapro","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.6061\/clinics\/2016(10)06_bib21","unstructured":"A single-center, open-label, randomized, crossover study of single subcutaneous administration to evaluate the pharmacokinetics of filgrastim in healthy volunteers of both sexes, under fasting conditions comparing investigational formulation produced by Eurofarma Laborat\u00f3rios and the originator formulation by Roche Produtos Qu\u00edmicos e Farmac\u00eduticos (Granulokine\u00ae) Study report JPJ46\/10, 2010 (data on file presented to ANVISA for marketing approval)."},{"issue":"13","key":"10.6061\/clinics\/2016(10)06_bib22","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1200\/JCO.2004.08.125","article-title":"Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study","volume":"22","author":"Alba","year":"2004","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.6061\/clinics\/2016(10)06_bib23","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1093\/annonc\/mdp574","article-title":"Development of a new G-CSF product based on biosimilarity assessment","volume":"21","author":"Gascon","year":"2010","journal-title":"Ann Oncol"},{"issue":"1","key":"10.6061\/clinics\/2016(10)06_bib24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/annonc\/mdg019","article-title":"International Pegfilgrastim 749 Study Group. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy","volume":"14","author":"Green","year":"2003","journal-title":"Ann Oncol"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222010456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222010456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:57:39Z","timestamp":1761721059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593222010456"},"secondary":[{"URL":"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5054975\/?report=classic","label":"PMC"},{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1807-59322016001000586&lng=en&nrm=iso&tlng=en","label":"SCIELO"}]},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016]]}},"alternative-id":["S1807593222010456"],"URL":"https:\/\/doi.org\/10.6061\/clinics\/2016(10)06","relation":{},"ISSN":["1807-5932"],"issn-type":[{"value":"1807-5932","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.6061\/clinics\/2016(10)06","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 CLINICS. Published by Elsevier Spain","name":"copyright","label":"Copyright"}]}}